Spots Global Cancer Trial Database for Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Official Title: A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (TIL or LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer
Study ID: NCT04614103
Conditions
Study Description
Brief Summary: This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer
Detailed Description: LN-145 is a ready-to-infuse TIL therapy that utilizes an autologous TIL manufacturing process, as originally developed by the NCI and further optimized by Iovance for the treatment of patients with metastatic NSCLC. The cell transfer therapy used in this study involves patients receiving a non-myeloablative (NMA) lymphodepleting preparative regimen, followed by infusion of autologous TIL, then finally followed by the administration of IL-2.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
City of Hope, Duarte, California, United States
UC San Diego Moores Cancer Center, La Jolla, California, United States
University of Southern California, Los Angeles, California, United States
Christiana Care Health System, Newark, Delaware, United States
University of Florida Health Cancer Center, Gainesville, Florida, United States
Sylvester Comprehensive Cancer Center, Miami, Florida, United States
AdventHealth Cancer Institute, Orlando, Florida, United States
H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Augusta University, Augusta, Georgia, United States
Rush University Medical Center, Chicago, Illinois, United States
University of Illinois Hospital & Health Sciences System, Chicago, Illinois, United States
Advocate Aurora Health, Park Ridge, Illinois, United States
University of Louisville, Louisville, Kentucky, United States
University of Maryland, Baltimore, Maryland, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Karmanos Cancer Institute, Detroit, Michigan, United States
Henry Ford Health System, Detroit, Michigan, United States
University of Nebraska Medical Center, Omaha, Nebraska, United States
MD Anderson Cooper, Camden, New Jersey, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
University of Rochester Medical Center, Rochester, New York, United States
University of North Carolina, Chapel Hill, North Carolina, United States
Novant Health - Charlotte, Charlotte, North Carolina, United States
Novant Health - Winston-Salem, Winston-Salem, North Carolina, United States
Atrium Health Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
University of Oklahoma, Oklahoma City, Oklahoma, United States
Oregon Health and Science University, Portland, Oregon, United States
Allegheny General Hospital, Natrona Heights, Pennsylvania, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Avera Medical Group Cancer Institute, Sioux Falls, South Dakota, United States
University of Tennessee Medical Center, Knoxville, Tennessee, United States
Baptist Cancer Center, Memphis, Tennessee, United States
Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
VCU Medical Center (Virginia Commonwealth University), Richmond, Virginia, United States
Seattle Cancer Care Alliance, Seattle, Washington, United States
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Centre Hospitalier de l'Universite de Montreal (CHUM), Montréal, , Canada
Universitätsklinikum Carl Gustav Carus, MK I, Dresden, , Germany
Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam, , Netherlands
University Hospital of Zurich/ Universitätsspital Zürich, Zürich, , Switzerland
Contact Details
Name: Iovance Biotherapeutics Study Team
Affiliation: Iovance Biotherapeutics
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
